A rheumatoid factor paradox: Inhibition of rituximab effector function

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Jones, Jonathan D ^a   Shyu, Irene ^a   Newkirk, Marianna M ^b   Rigby, William F C ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; FC RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; PROPIDIUM IODIDE; RHEUMATOID FACTOR; RITUXIMAB; ANTIRHEUMATIC AGENT; COMPLEMENT; MONOCLONAL ANTIBODY;

ARTICLE; CELL ADHESION; CELL DEATH; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; RHEUMATOID ARTHRITIS; B LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; HUMANS; RHEUMATOID FACTOR;

EID: 84872801503     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4152     Document Type: Article

References (38)

1. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163. 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3, 10643712.
2. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, Barton A. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58:359-369. 10.1002/art.23149, 3001034, 18240242.
3. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arth Res Therap 2006, 8:R12.
4. Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum 2011, 63:3681-3691. 10.1002/art.30596, 22127691.
5. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatol 2009, 48:1557-1559.
6. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70:1575-1580. 10.1136/ard.2010.148759, 21571731.
7. Artandi SE, Calame KL, Morrison SL, Bonagura VR. Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci USA 1992, 89:94-98. 10.1073/pnas.89.1.94, 48182, 1370358.
8. Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, Beale D, Taussig MJ, Sutton BJ. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997, 4:374-381. 10.1038/nsb0597-374, 9145108.
9. Stuber F, Lee SK, Bridges SL, Koopman WJ, Schroeder HW, Gaskin F, Fu SM. A rheumatoid factor from a normal individual encoded by VH2 and VκII gene segments. Arthritis Rheum 1992, 35:900-904. 10.1002/art.1780350808, 1322670.
10. Koopman WJ, Schrohenloher RE. In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults. J Immunol 1980, 125:934-939.
11. He X, Goronzy JJ, Weyand CM. The repertoire of rheumatoid factor-producing B cells in normal subjects and patients with rheumatoid arthritis. Arthritis Rheum 1993, 36:1061-1069. 10.1002/art.1780360806, 8343183.
12. Trendelenberg M, Schifferli JA. Cryoglobulins in chronic hepatitis C infection. Clin Exp Immunol 2003, 133:153-155. 10.1046/j.1365-2249.2003.02198.x, 1808770, 12869018.
13. Newkirk MM. Rheumatoid factors: host resistance or autoimmunity?. Clin Immunol 2002, 104:1-13. 10.1006/clim.2002.5210, 12139942.
14. Carson DA, Chen PP, Kipps TJ. New roles for rheumatoid factor. J Clin Invest 1991, 87:379-383. 10.1172/JCI115007, 295087, 1991824.
15. Vaughan JH. Pathogenetic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum 1993, 36:1-6. 10.1002/art.1780360102, 8424828.
16. Winchester R. A golden anniversary: recognition that rheumatoid arthritis sera contain autoantibodies specific for determinants on native IgG molecules. J Immunol 2007, 178:1227-1228.
17. Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 1957, 105:425-438. 10.1084/jem.105.5.425, 2136709, 13428913.
18. Winchester RJ, Agnello V, Kunkel HG. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis: partial characterization and relationship to lowered complement levels. Clin Exp Immunol 1970, 6:689-706. 1712723, 4097828.
19. Ishikawa H, Smiley JD, Ziff M. Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. Arthritis Rheum 1975, 18:541-551. 10.1002/art.1780180603, 1106425.
20. Hannestad K, Mellbye OJ. Rheumatoid factor in synovial effusions: local production and consumption. Clin Exp Immunol 1967, 2:501-509. 1578860, 4167750.
21. Luthra HS, McDuffie FC, Hunder GG, Samayoa EA. Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monoclonal rheumatoid factor. J Clin Invest 1975, 56:458-466. 10.1172/JCI108112, 436606, 125289.
22. Harris J, Vaughan JH. Transfusion studies in rheumatoid arthritis. Arthritis Rheum 1961, 4:47-55. 10.1002/art.1780040105, 13711743.
23. Sabharwal UK, Vaughan JH, Fong S, Bennett PH, Carson DA, Curd JG. Activation of the classical pathway of complement by rheumatoid factors: assessment by radioimmunoassay for C4. Arthritis Rheum 1982, 25:161-167. 10.1002/art.1780250208, 7066047.
24. Vaughan JH, Jacox RF, Noell P. Relation of intracytoplasmic inclusions in joint fluid leukocytes to anti-IgG globulins. Arthritis Rheum 1968, 11:135-144. 10.1002/art.1780110203, 4171445.
25. Ng YC, Peters K, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum 1988, 31:99-107. 10.1002/art.1780310114, 3345233.
26. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanism of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837. 10.1016/j.molimm.2007.06.151, 17768100.
27. Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum 2012, 64:3111-3118. 10.1002/art.34560, 22674374.
28. Beum PV, Kennedy AD, Williams ME, Lindofer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from Mantle Cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-2609.
29. Newkirk MM, Mageed RA, Jefferis R, Chen PP, Capra JD. The complete amino acid sequences of the variable regions of two human IgM Rheumatoid Factors, BOR and KAS of the Wa idiotypic family reveals a restricted usage of heavy and light chain variable and joining region gene segments. J Exp Med 1987, 166:550-564. 10.1084/jem.166.2.550, 2189595, 2439644.
30. Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, Taussig MJ. Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol 2007, 368:1321-1331. 10.1016/j.jmb.2007.02.085, 17395205.
31. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012, 526:146-153. 10.1016/j.abb.2012.02.011, 22387378.
32. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000, 164:4178-4184.
33. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994, 57:1-127.
34. Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 2000, 164:5313-5318.
35. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988, 332:738-740. 10.1038/332738a0, 3258649.
36. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005, 174:817-826.
37. Van Snick JL, Van Roost E, Markowetz B, Cambiaso CL, Masson PL. Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol 1978, 8:279-285. 10.1002/eji.1830080412, 668802.
38. Walport MJ. Complement. First of two parts. N Engl J Med 2001, 344:1058-1066. 10.1056/NEJM200104053441406, 11287977.